AstraZeneca PLC (LON:AZN), The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of..

AstraZeneca PLC (LON:AZN), today announced full year results for the Q4 2018. The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8%..

AstraZeneca Plc (LON:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897,..

AstraZeneca Plc (LON:AZN) and its global biologics research and development arm, MedImmune, has completed the agreement to sell its US rights to Synagis (palivizumab), used for the prevention of serious..

AstraZeneca Plc (LON:AZN) today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic..

AstraZeneca Plc (LON:AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has now received formal marketing authorisation from the National Medical Products Administration (NMPA)..

AstraZeneca PLC (LON:AZN) today announced the following changes in respect of Non-Executive Directors. New Non-Executive Director With effect from 1 January 2019, Professor Tony Mok is appointed as a Non-Executive..

AstraZeneca Plc (LON:AZN) announced the completion of agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan)..

AstraZeneca Plc (LON:AZN) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis..

AstraZeneca Plc (LON:AZN) and MedImmune, its global biologics research and development arm, announced today final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global..

AstraZeneca Plc (LON:AZN) today announced the agreed sale of US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus..

AstraZeneca Plc (LON:AZN) announced today positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at..

AstraZeneca PLC (LON:AZN), today announced Q3 2018 results. Product Sales increased by 4% in the year to date (2% at CER1), supporting full-year guidance. For the quarter, Product Sales increased..

AstraZeneca Plc (LONAZN) has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma,..

AstraZeneca Plc (LON:AZN) announced the agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo..

AstraZeneca Plc (LON:AZN), and its global biologics research and development arm MedImmune, announced today a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating..

AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced today detailed results from the Phase III SOLO-1 trial..

AstraZeneca Plc (LON:AZN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for..

AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by..

AstraZeneca Plc (LON:AZN) completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in..